During ASCO 2019, Chicago, US, the MM Hub spoke to Philip L. McCarthy, Roswell Park Comprehensive Cancer Center, Buffalo, US, about the evolving treatment paradigms in newly diagnosed multiple myeloma (NDMM). He spoke firstly about the exciting news from the International Myeloma Working Group (IMWG) of a new risk stratification system for smoldering myeloma (SMM) as a way of recognizing high-risk patients. He noted this was significant as the field is evolving and we are continuously searching for factors to indicate whether patients should be treated early, or observed. Secondly, he stated that the new data presented at ASCO by Sagar Lonial, showed lenalidomide was superior to observation alone in high-risk SMM. Lastly, Philip McCarthy discussed the risk analysis from the FORTE trial (carfilzomib + lenalidomide + dexamethasone [KRd] with or without transplant).
The European School of Haematology (ESH) is a not for profit institution for the dissemination of information and lifelong learning founded in 1985 to promote and facilitate access to state-of-the-art and cutting-edge knowledge in haematology and related disciplines at the European level. ESH Conferences present state-of-the-art science and insight into new developments in the fields of basic, clinical and therapeutic research in Haematology